Comparative Pharmacology
Head-to-head clinical analysis: ACIPHEX SPRINKLE versus PREVACID NAPRAPAC 500 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACIPHEX SPRINKLE versus PREVACID NAPRAPAC 500 COPACKAGED.
ACIPHEX SPRINKLE vs PREVACID NAPRAPAC 500 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rabeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
Lansoprazole inhibits gastric acid secretion by irreversibly binding to the H+/K+ ATPase (proton pump) in gastric parietal cells. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
20 mg orally once daily as delayed-release capsules; maximum dose 40 mg per day.
One tablet of naproxen 500 mg and one capsule of lansoprazole 15 mg taken together orally once daily. Naproxen component: 500 mg orally twice daily. Lansoprazole component: 15 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in healthy subjects; prolonged in CYP2C19 poor metabolizers (up to 3-4 hours). Clinically, the short half-life results in rapid clearance but sustained acid suppression due to irreversible binding to the proton pump.
Naproxen: 12–17 hours (mean ~14 h), prolonged with renal impairment. Esomeprazole: 1–1.5 hours (increase to 2–3 h with CYP2C19 poor metabolizers or hepatic impairment).
Primarily hepatic metabolism (CYP2C19 and CYP3A4); <1% excreted unchanged in urine; approximately 90% of the dose excreted as metabolites in urine and feces via biliary elimination.
Naproxen: 95% renal (primarily as unchanged drug and metabolites, including 6-O-desmethyl naproxen), <5% biliary/fecal. Esomeprazole: 80% renal (as metabolites, primarily hydroxyesomeprazole and desmethyl-esomeprazole, with ~1% unchanged), 20% fecal (via bile).
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination